The company clarified that the infusion would be made without any equity dilution.

Managing director and CEO Shazad Rustomji said the move demonstrates his personal commitment to advancing the company's self-reliance goals in the fluorochemicals manufacturing segment. This infusion ensures work on our R-32 project begins without delay, while maintaining our capital structure, he noted.

Stallion India Fluorochemicals is a specialized leader in the refrigerants and industrial gases sector. It is engaged in processing, blending, and distributing gases across diverse industries including air conditioning, refrigeration, fire-fighting, semiconductor manufacturing, pharmaceuticals, automotive, and glass production. The company operates four strategic manufacturing facilities located in Khalapur, Ghiloth, Manesar, and Panvel, specializing in the debulking, blending, and processing of gases.

The company reported a net profit of Rs 11.41 crore in Q2 FY26, a sharp rise from Rs 0.85 crore in Q2 FY25. Revenue grew 56.3% year-on-year to Rs 105.56 crore, while EBITDA surged to Rs 15.77 crore from Rs 2.35 crore a year ago. Profit before tax stood at Rs 15.24 crore, compared with Rs 0.55 crore in the same quarter last year.

The stock debuted on the bourses on 23 January 2025, listing at Rs 120, a premium of 33.33% over the issue price of Rs 90. The initial public offer (IPO) of Stallion India Fluorochemicals was subscribed 188.38 times. The issue was open for bidding from 16 to 20 January 2025, with a price band fixed between Rs 85 and Rs 90 per share.

The stock hit a record high of Rs 424.20 on 17 October 2025. Since then, it has been on a downward spiral, declining 41.62% to the current level.